Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in Sjogren's Disease-Associated Polyneuropathy
NCT07760818Phase 2Not yet recruiting
- Sponsor
- argenx
- Start
- Aug 2026
- Primary completion
- Jul 2028
01
Overview
A Phase 2 trial of efgartigimod alfa + hyaluronidase-qvfc in Sjögren's syndrome, polyneuropathy, sponsored by argenx. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Sjögren's syndromepolyneuropathy
Beyond the preview
Go deeper on NCT07760818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760818.